FDA approval of expanded indication of Illuccix in the US
Filed with ASX · · 3 pages · English
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- 2022 Full Year Results Presentation
- Appendix 4E and 2022 Annual Report
- 2022 Full Year Results Release
- Telix Full Year Results and Investor Conference Call Details
- Q4 2022 Business update to accompany quarterly results
Later from Telix Pharmaceuticals
- Illuccix European Marketing Authorisation Application Update
- Telix Preclinical Development of Radiolabelled Olaratumab
- Appendix 4C and Activities Report - March 2023 Quarter
- Q1 2023 Business update to accompany quarterly results
- Telix Accelerates AI Development with Dedicaid Acquisition
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals